TTNP (Titan Pharmaceuticals) Institutional Ownership : 1.84% (As of Jan. 19, 2025)

View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Titan Pharmaceuticals's institutional ownership is 1.84%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Titan Pharmaceuticals's Insider Ownership is 21.06%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Titan Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 81.60%.

Titan Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Titan Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals Institutional Ownership Chart

Titan Pharmaceuticals Historical Data

The historical data trend for Titan Pharmaceuticals can be seen below:

	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31
Institutional Ownership	0.62	0.62	0.62	0.70	0.69	0.69	0.67	0.71	0.71	0.70

Titan Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Titan Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Executives

Seow Gim Shen	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd.	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo	director	1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey	director	3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg	director	710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi	director	44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe	director, officer: President and COO	400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong	10 percent owner	NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar	director, 10 percent owner, officer: Chief Executive Officer	VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc	other: Member of 10% owner group	1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers	director	630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab	director	C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin	director, officer: Executive Chairman	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg	officer: See Remarks	400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080